Beijing Tongrentang (SHA:600085) issued a formal undertaking to address potential horizontal competition issues after becoming a controlling shareholder following its acquisition of a 28.48% stake in Cachet Pharmaceutical (SHE:002462).
The company said Cachet's pharmaceutical wholesale and logistics business is "significantly different" from Tongrentang's traditional Chinese medicine production and sales, according to a Wednesday aftermarket filing with the Shanghai bourse.
"Therefore, Cachet does not constitute horizontal competition with a material adverse impact on Tongrentang," the company added.